Drug Trial Radar · NCT06909253
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
May 15, 2025
Primary completion
Dec 31, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 3, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.
Conditions
- Myasthenia Gravis, Generalized
Interventions
RavulizumabDrug
Ravulizumab, concentrate for solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total scoreTime frame: at 6 month
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Bydgoszcz, Poland · Recruiting
Research Site
Gdansk, Poland · Recruiting
Research Site
Katowice, Poland · Recruiting
Research Site
Krakow, Poland · Recruiting
Research Site
L DZ, Poland · Recruiting
Research Site
Lublin, Poland · Recruiting
Research Site
Poznan, Poland · Recruiting
Research Site
Szczecin, Poland · Recruiting
Research Site
Szczecin, Poland · Withdrawn
Research Site
Warsaw, Poland · Recruiting
Research Site
Wroclaw, Poland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.